Непрошеные гости: избыточный бактериальный рост в тонкой кишке. Что делать?

1. Янковский Д.С. Состав и функции микробиоценозов различных биотопов человека. Здоровье женщины. 2003; 4 (16): 145–8.
2. Плотникова Е.Ю., Краснова М.В., Баранова Е.Н. и др. Дыхательные водородные тесты в диагностике синдрома избыточного бактериального роста. Диагностика заболеваний желудочно-кишечного тракта по выдыхаемому воздуху. Сборник научных статей III Международного конкурса научно-исследовательских работ. СПб., 2012; с. 64–70.
3. Белоусова Е.А. Синдром избыточного бактериального роста тонкой кишки в свете общей концепции о дисбактериозе кишечника. Взгляд на проблему. Фарматека. 2009; 2.
4. Маев И.В., Самсонов А.А. Терапевтическая тактика при синдроме избыточного бактериального роста в тонкой кишке. Cons. Med. 2007; 7: 45–56.
5. Kopacova M, Bures J, Cyrany J et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16 (24): 2978–90.
6. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001; 7: 167–202.
7. Medzhitov R, Janeway C. Innate immune recognition: mechanisms and pathways. J. Immunol Rev 2000; 173: 89–97.
8. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852–8.
9. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503–6.
10. Lupascu A, Gabrielli M, Lauritano EC et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 1157–60.
11. Nucera G, Gabrielli M, Lupascu A et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 21: 1391–5.
12. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. Am J Gastroenterol 2003; 98: 412–9.
13. Singh VV, Toskes PP. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol 2004; 7 (1): 19–28.
14. Василенко В.В. Дисбактериоз – синдром раздраженного кишечника: эссе-анализ проблемы. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2000; 6: 10–3.
15. Ардатская М.Д. Синдром избыточного бактериального роста и нарушение процессов пищеварения и всасывания. Поликлиника. 2009; 2: 38–40.
16. Передерий В.Г., Ткач С.М., Сизенко А.К., Швец О.В. Клиническое применение водородных дыхательных тестов в гастроэнтерологии. Сучасна гастроентерологія. 2010; 4 (54): 26–33.
17. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M. 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009; 29 (Suppl. 1): 1–49.
18. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503–6.
19. Riordan SM, McIver CJ, Walker BM et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91: 1795–803.
20. Pimentel M, Constantino T, Kong Y et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 2004; 49: 73–7.
21. Perman JA, Modler S, Barr RG et al. Fasting breath hydrogen concentration: normal values and clinical application. Gastroentero-logy 1984; 87: 1358–63.
22. Drossman DA. Treatment for Bacterial Overgrowth in the Irritable Bowel Syndrome. Comment on: Ann Intern Med. 2006; 145 (8): 557–63.
23. Madrid AM, Hurtado C, Venegas M et al. Long-term treatment with cis-apride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001; 96: 1251–55.
24. Edmunds MC, Chen JD, Soykan I et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther 1998; 12: 167–74.
25. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461–7.
26. Haboubi NY, Lee GS, Montgomery RD. Duodenal mucosal morphometry of elderly patients with small intestinal bacterial overgrowth: Response to antibiotics treatment. Age Ageing 1991; 20: 29–32.
27. Bishop WP. Breath hydrogen testing for small bowel bacterial overgrowth – a lot of hot air? J Pediatr Gastroenterol Nutr 1997; 25: 245–6.
28. Di Stefano M, Miceli E, Missanelli A et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther 2005; 21: 985–92.
29. Bouhnik Y, Alain S, Attar A et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94: 1327–31.
30. Di Stefano M, Malservisi S, Veneto G et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551–6.
31. Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117: 794–7.
32. Castiglione F, Rispo A, Di Girolamo E et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1107–12.
33. Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111–6.
34. Vanderhoof JA, Young RJ. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth. Treatment of bacterial overgrowth. UpToDate online, vol 18.1; Wellesley, 2010. Available from: http://www.uptodate.com.
35. Ojetti V, Lauritano EC, Barbaro F et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009; 5: 675–82.
36. Lauritano EC, Gabrielli M, Lupascu A et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 31–5.
37. Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009; 15: 2628–31.
38. Di Stefano M, Strocchi A, Malservisi S et al. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000; 14: 1001–8.
39. Scarpellini E, Gabrielli M, Lauritano CE et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25: 781–6.
40. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007; 25: 1271–81.
41. Yang J, Lee HR, Low K et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53 (1): 169–74.
42. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006; 145 (8): 557–63.
43. Sharara AI, Aoun E, Abdul-Baki H et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101 (2): 326–33.
44. Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with rifaximin. World J Gastroenterol 2009; 15 (21): 2628–31.
45. Low K, Hwang L, Hua J et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010; 44 (8): 547–50.
46. Pimentel M, Lembo A, Chey WD et al. For the TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364 (1): 22–32.
47. Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011; 4: 43–8.
48. Gaon D, Garmendia C, Murrielo NO et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina 2002; 62: 159–63.
49. Stotzer PO, Blomberg L, Conway PL et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996; 28: 615–9.
50. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007; 9: 463–7.
51. Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103: 2031–5.

Е.Ю.Плотникова, М.В.Краснова, Е.Н.Баранова, М.В.Борщ

ГБОУ ВПО КемГМА Минздрава РФ